Company news

Dyadic International, Inc. news in 2023

Dyadic International, Inc.'s news releases, calls and decks from 2023, newest first.

View company

Dyadic Announces Top-Line Results from its Successful Phase 1 Clinical Trial for a First-in-Human Filamentous Fungal-Based Vaccine Candidate

November 28, 2023

Dyadic Announces Third Quarter 2023 Financial Results and Highlights Recent Company Progress

November 7, 2023

Dyadic to Report Third Quarter 2023 Financial Results on Wednesday, November 8, 2023

October 24, 2023

Dyadic Appoints Doug Pace to Its Executive Leadership Team

October 8, 2023

Dyadic’s C1 Platform Selected by the Vaccine and Immunotherapy Center (“VIC”) at Massachusetts General Hospital as Part of VIC’s $5.88 Million Award by U.S. DoD to Develop a Self-Assembling Vaccine (SAV) Platform for Rapid Production of Prophylactic V...

October 4, 2023

Dyadic and bYoRNA Announce a Collaboration Targeting the Production of Abundant, Low-Cost mRNA From C1-Cells

September 25, 2023

Dyadic Announces Development and License Agreement to Commercialize Animal-Free Alternative Proteins Using Dapibus™

September 18, 2023

Dyadic Announces Second Quarter 2023 Financial Results and Highlights Recent Company Progress

August 8, 2023

Dyadic Announces Continued Progress Towards Commercialization of Animal-Free Recombinant Serum Albumin

August 6, 2023

Dyadic to Report Second Quarter 2023 Financial Results on Wednesday, August 9, 2023

July 25, 2023

Dyadic Provides Phase 1 Clinical Trial Update for its Recombinant Protein RBD Vaccine Candidate

July 23, 2023

Dyadic Announced an MoU with Bangladesh’s State-Owned Pharmaceutical Company to Facilitate Biopharmaceutical Research and Biomanufacturing Capacity

June 20, 2023

Dyadic Announces First Quarter 2023 Financial Results and Highlights Recent Company Progress

May 9, 2023

Dyadic Announces Collaboration to Commercialize Animal-Free Alternative Proteins Using Dapibus™

May 7, 2023

Dyadic to Report First Quarter 2023 Financial Results on Wednesday, May 10, 2023

April 25, 2023

Dyadic Receives U.S. Patent for Manufacturing Seasonal and Pandemic Influenza Vaccines from its Proprietary C1 Protein Production Platform

April 17, 2023

Dyadic Announces Expanded Licensing Agreement to Develop and Commercialize Vaccines and Biologics for African Continent

April 11, 2023

Dyadic Reports 2022 Year End Results and Recent Company Progress

March 28, 2023

Dyadic to Report 2022 Year End Financial Results on Wednesday, March 29, 2023

March 14, 2023

Dyadic Provides Phase 1 Clinical Trial Update for its DYAI-100 COVID-19 Recombinant Protein RBD Booster Vaccine Candidate

March 6, 2023

Dyadic Announces Initiation of Dosing of First-In-Human Phase 1 Trial to Demonstrate Clinical Safety and Antibody Response in Humans for DYAI-100 COVID-19 Recombinant Protein RBD Booster Vaccine Candidate

January 23, 2023

Dyadic Announces Sale of Equity Interest in Alphazyme

January 18, 2023

Calls in 2023

Decks in 2023